Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
On 30 Jul 2025 AtriCure, Inc. ("ATRC") filed a Form S-8 with the SEC to register 1,700,000 additional shares of common stock for issuance under its 2023 Stock Incentive Plan. Because the company is a large accelerated filer, the shares become eligible for grant immediately upon effectiveness.
The filing incorporates by reference the company’s 2024 Form 10-K, 2025 Form 10-Qs and a recent Form 8-K, and includes standard undertakings and indemnification language. Keating Muething & Klekamp PLL supplied the legal opinion, while Deloitte & Touche LLP provided the auditor’s consent. No new financial statements, pricing terms or selling shareholder information are presented.
The registration expands the equity pool used to attract, retain and motivate employees and directors; however, issuance of the newly registered shares could dilute existing shareholders when awards vest or are exercised.
AtriCure (ATRC) Q2-25 10-Q highlights: Revenue rose 17.1% YoY to $136.1 M, driven by 41% growth in Pain Management and 19% in Appendage Management; Minimally Invasive Ablation fell 34%. International sales advanced 23% (20% cc). Six-month revenue reached $259.8 M, +15.4% YoY.
Gross margin held at 74.5%. Operating loss narrowed to $6.2 M from $7.2 M; net loss improved to $6.2 M (-$0.13 EPS) vs. $8.0 M (-$0.17). YTD net loss nearly halved to $12.9 M. Cash flow from operations swung to +$10.6 M (vs. -$13.6 M). Cash & equivalents ended at $117.8 M; long-term ABL debt unchanged at $61.9 M, leaving $61.9 M in unused capacity.
R&D expense jumped 43% to $29.3 M, including a $5 M milestone for the pulsed-field ablation (PFA) Cooperation Agreement. SG&A rose 6.5% on headcount. Key milestones: FDA 510(k) clearances for AtriClip PRO-Mini and cryoICE cryoXT (launches 2H-25); completion of 6,500-patient LeAAPS stroke-prevention trial enrollment.
Risk factors: a Delaware suit from former SentreHEART holders seeks up to $260 M over PMA milestone; management deems loss not probable/estimable. Minimally invasive revenue weakness and flat margins bear monitoring.